Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design

Publisher： Bentham Science Publishers

E-ISSN： 1875-6360|6|2|138-144

ISSN： 1573-3971

Source： Current Rheumatology Reviews, Vol.6, Iss.2, 2010-05, pp. : 138-144

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease

By Koutroumpas Athanasios Ziogas Athanasios Alexiou Ioannis Barouta Georgia Sakkas Lazaros

Clinical Rheumatology, Vol. 29, Iss. 10, 2010-10 ,pp. : 1167-1168

Springer Publishing Company

Access to resources Recommend Favorite

Outcome Measures for Clinical Trials in Interstitial Lung Diseases

Current Respiratory Medicine Reviews, Vol. 11, Iss. 2, 2015-01 ,pp. : 163-174

Bentham Science Publishers

Access to resources Recommend Favorite

Outcome Measures for Clinical Trials in Interstitial Lung Diseases

Current Respiratory Medicine Reviews, Vol. 11, Iss. 2, 2015-08 ,pp. : 163-174

Bentham Science Publishers

Access to resources Recommend Favorite

Systemic Sclerosis Associated Interstitial Lung Disease

Current Respiratory Medicine Reviews, Vol. 11, Iss. 2, 2015-01 ,pp. : 110-118

Bentham Science Publishers

Access to resources Recommend Favorite

Systemic Sclerosis Associated Interstitial Lung Disease

Current Respiratory Medicine Reviews, Vol. 11, Iss. 2, 2015-08 ,pp. : 110-118

Bentham Science Publishers

Access to resources Recommend Favorite